Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOB015B topical solution in pediatric distal subungual onychomycosis
2022-001797-59Phase 2Active
- Sponsor
- Moberg Pharma AB
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Terclara in onychomycosis, sponsored by Moberg Pharma AB. Primary endpoint: Treatment success at Week 48. Started Nov 2022; status: active.
02
Drugs
Terclara
03
Conditions
onychomycosis
Beyond the preview
Go deeper on 2022-001797-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001797-59.